KODK · Eastman Kodak Company

Current Thesis

The fat pitch already fired. KODK's $1.023B KRIP pension reversion completed December 2, 2025 ~$767M reverted to the company ($609M cash + $158M non-cash), $312M prepaid the term loan down to a $200M balance, and after a $153M excise tax the company sits net-cash >$300M. That de-risking re-rate is what drove the stock from a ~$6 March base to a $14.87 52-week high into early May. A pivot-top sell signal fired May 6, 2026 and the name corrected ~32% to ~$9.73 (June 4–5), where it has gone sideways for roughly three weeks. The pension binary is realized and in the price; what remains is a slower legacy-pivot story battery-electrode coating (Ateios/RaiCore) plus pharma reagents inside a redefined Advanced Materials & Chemicals segment with no scheduled catalyst in the next 30 days. Momentum has rolled over.

Bull Case

• Balance sheet transformed, not narrated: pension reversion completed Dec 2, 2025 freed $1.023B; ~$767M reverted, $312M prepaid the term loan to a $200M balance, net-cash position now >$300M after the $153M excise tax. A debt-burdened sub-$1.5B-cap legacy name became net-cash in one event the re-rate had a real anchor.
• Operating inflection three quarters deep: FY2025 revenue $1.069B (+2%), operational EBITDA $62M (+138% YoY); Q4 2025 (reported Mar 13, 2026) revenue $290M (+9%), EBITDA $22M vs $9M; Q1 2026 (reported May 7, 2026) revenue $265M (+7%), gross margin 22% vs 19%, operational EBITDA $15M vs $2M.
• AM&C pivot has shipping product lines: Mar 23, 2026 expansion of Ateios Systems' RaiCore battery-electrode platform across LFP/NMC/LCO chemistries, PFAS-free, using Kodak coating expertise for production-scale manufacturing; Jan 26, 2026 pharma portfolio added four regulated reagents (PBS 1X and Water-for-Injection variants) for biopharma/CDMOs. AM&C now runs ~$76M/quarter across five lines.
• Legacy base still funds the pivot: Print revenue $180M in Q1 2026 (+9% YoY) the imaging core is growing, not collapsing on the timeline bears modeled.
• Spin/activist optionality cleaner post-reversion: net-cash runway makes an AM&C carve-out or strategic review credible; the May annual meeting (proxy filed Apr 9, 2026) keeps that thread live.

Bear Case

• The binary already paid: reversion closed Dec 2, 2025 and the re-rate ran April–May to $14.87. A buyer at ~$9.7 is paying after the event, chasing a second leg that needs a new catalyst.
• Momentum rolled over: pivot-top sell signal May 6, 2026, down ~32% into late May ($9.82 on May 22), then three weeks of drift around $9.5–9.8. The trend leg is spent.
• GAAP picture deteriorating under the EBITDA gloss: Q1 2026 GAAP net loss $16M vs $7M a year ago; EPS −$0.16 vs −$0.12; net loss widened ~60% YoY even as operational EBITDA improved.
• AM&C growth decelerated: AM&C revenue +3% YoY in Q1 2026 ($76M vs $74M), trailing Print's +9% and far from the "meaningful offtake revenues 2H 2026" inflection. No named, signed offtake was disclosed on the May 8 call.
• No insider conviction: insiders net sellers by ~$5.7M over the trailing 12 months no Form 4 buying into the dip.
• Dilution + no scheduled catalyst: the ATM shelf is an overhang at post-run prices, and nothing forces a re-rate in the next 30 sessions.

Setup & Price Structure

Last ~$9.73 (June 4–5, 2026). 52-week range $4.94–$14.87, one-year average ~$7.83; YTD +41%, trailing-year +88%. The sequence: ~$6 base in March → new 52-week high $12.48 on April 29 → $14.87 high into early May → pivot-top sell signal May 6 → ~32% correction → $9.82 on May 22 → drifting ~$9.7 now. The rising 200-day sits in roughly the $7.0–7.5 zone, so price holds well above its long-term trend, but a 50-day now rolling over near ~$10.5–11 sits overhead short-term structure is broken. Consolidation shelf is ~$9.50; a daily close below $9.00 on >3M shares opens air toward the $7 200-day and then the $6 base. Re-arming the uptrend requires a volume reclaim of ~$11, with $12.48 and $14.87 the prior-high resistance shelf. This is digestion of a name that already tripled off its low a clean re-entry would need a higher-low base above the 50-day plus a named AM&C offtake, not a mid-range grab.

Catalyst Calendar (next 30 days)

• No scheduled binary in the window June 7 July 7, 2026.
• Q2 2026 earnings ~early-to-mid August 2026 (est.) Q1 reported May 7, so the print is outside the 30-day window; respect a 3-trading-day pre-print blackout when it approaches.
• Unscheduled but live: any AM&C offtake/contract 8-K (battery-electrode or pharma-reagent customer at scale) could hit any day the single biggest swing factor for a second leg.
• Watch: a prospectus supplement / ATM issuance disclosure in any new 8-K given the elevated post-run price.

What Would Change Our Mind

• Bull flip (upgrade from probe): a named, signed AM&C offtake with revenue scale plus a volume reclaim of the ~$11 50-day forming a higher low that re-arms the legacy-pivot leg.
• Cleaner re-entry: a controlled pullback to the rising 200-day (~$7) that holds with a higher-low and absorption volume offers better risk/reward than chasing the $9.7 mid-range.
• Bear confirmation: a daily close below $9.00 on >3M shares (digestion fails → $7, then $6), or a Q2 print with AM&C flat/down sequentially and still no signed offtake.
• Squeeze re-arm: a fresh short-interest spike (>20% of float) into a contract headline could revive the layer, though the April–May run likely burned most of that fuel.

Correlation Notes

The April–May advance was idiosyncratic pension de-risking and the AM&C narrative not a clean beta to the rare-earth/onshoring complex; correlation to MP/USAR is loose (~0.35–0.45), so KODK should not be assumed to track REE names. The Ateios/RaiCore tie gives a faint read-through to battery-electrode and PFAS-free-materials sentiment, but KODK's revenue exposure there is still immaterial. The Print segment maps to commercial-print/packaging demand (industrial cyclical) and is uncorrelated to the AM&C story carrying the multiple. With a ~80M-share float and persistent retail attention, KODK trades on its own headlines and squeeze mechanics far more than any sector factor; SPY/macro beta is secondary to single-name catalysts.